Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT02200757. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy
Study identification
- NCT ID
- NCT02200757
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Enrollment
- 135 participants
Conditions and interventions
Conditions
Interventions
- Aldoxorubicin Drug
- Topotecan Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 19, 2015
- Primary completion
- May 14, 2017
- Completion
- May 14, 2017
- Last update posted
- Jun 24, 2024
2015 – 2017
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| City of Hope Medical Group | Pasadena | California | 91030 | — |
| Cancer Specialists of North Florida-Fleming Island | Fleming Island | Florida | — | — |
| Northwest Georgia Oncology Centers, P.C. | Marietta | Georgia | 30060 | — |
| James Graham Brown Cancer Center | Louisville | Kentucky | 40202 | — |
| Oncology Hermatology Care, Inc. | Cincinnati | Ohio | 45242 | — |
| Northwest CCOP Kaiser Permanente | Portland | Oregon | 97227 | — |
| Penn State Hershey Cancer Institute | Hershey | Pennsylvania | 17033 | — |
| Tennessee Oncology | Chattanooga | Tennessee | 37404 | — |
| Tennessee Cancer Specialists | Knoxville | Tennessee | 37909 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02200757, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 24, 2024 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02200757 live on ClinicalTrials.gov.